Compare Heron Therapeutics Inc (HRTX) vs Newmont Corporation (NEM) Price & Performance

Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.

HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.

Newmont Corporation (NEM) trades at $112.98, up 7.16% over 24 hours, reflecting strong momentum amid record gold prices. The stock exhibits bullish technical signals with moving averages aligned positively, though oscillators suggest overbought conditions. Fundamentally, the company reported robust earnings, with Q2 2026 EPS of $2.10 beating estimates, and annual revenue growth from $11.9B in 2022 to $22.7B in 2025. Recent news highlights a $1.95B settlement with Barrick Mining, resolving Nevada disputes and enhancing strategic flexibility.

Outlook remains positive with a consensus price target of $133, implying 17.8% upside, supported by 75.7% analyst buy ratings. Key opportunities include strong free cash flow generation and production guidance maintenance. Risks involve potential cost pressures in H2 2026, gold price volatility, and insider stock sales by the CEO and CFO in early August 2026.